MBX insiders were on both sides of the trade this year. Buys came to roughly $1.1 million (two buyers), sales to $2.7 million (two sellers).
The largest purchase came from Hawryluk P. Kent (CEO), about $526,000. C-suite participation is part of the picture here.
173 investment managers listed MBX in their latest 13F filings (Q2 2026); more funds bought than sold. Quarter by quarter: 2 quarters in a row of net selling by insiders. Insiders bought in 5 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | Azoulay Salomon | Executive Officer | Sell | 370 | $65.77 | $24K | SEC |
| May 11, 2026 | Azoulay Salomon | Executive Officer | Sell | 55,000 | $38.38 | $2.1M | SEC |
| May 11, 2026 | Azoulay Salomon | Executive Officer | Sell | 15,003 | $38.30 | $575K | SEC |
| May 8, 2026 | Azoulay Salomon | Executive Officer | Sell | 231 | $29.54 | $7K | SEC |
| May 8, 2026 | Hawryluk P. Kent | CEO | Sell | 607 | $29.54 | $18K | SEC |
| Mar 16, 2026 | Hawryluk P. Kent | CEO | Buy | 18,500 | $28.41 | $526K | SEC |
| Oct 21, 2025 | Hawryluk P. Kent | CEO | Buy | 20,000 | $13.64 | $273K | SEC |
| Oct 20, 2025 | Hoerter Steven L. | Director | Buy | 20,000 | $13.25 | $265K | SEC |
| Sep 30, 2025 | FHMLS X, L.P. | Director | Buy | 666,666 | $18.00 | $12.0M | SEC |
| Apr 10, 2025 | Pescovitz Ora H. | Director | Buy | 7,693 | $5.89 | $45K | SEC |
| Feb 19, 2025 | GORDON CARL L | Director | Buy | 94,100 | $10.84 | $1.0M | SEC |
| Feb 19, 2025 | OrbiMed Genesis GP LLC | Director | Buy | 94,100 | $10.84 | $1.0M | SEC |
| Feb 19, 2025 | OrbiMed Genesis GP LLC | Director | Buy | 17,962 | $9.90 | $178K | SEC |
| Feb 19, 2025 | OrbiMed Genesis GP LLC | Director | Buy | 49,070 | $10.84 | $532K | SEC |
| Feb 19, 2025 | OrbiMed Genesis GP LLC | Director | Buy | 29,540 | $9.85 | $291K | SEC |
In the last 12 months MBX Biosciences, Inc. insiders made open-market purchases worth about $1.1 million and sales worth about $2.7 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in MBX was filed on 2026-08-05.
173 investment managers reported holding MBX in SEC Form 13F filings for Q2 2026.
No congressional trades in MBX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).